# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ernest Hemingway (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET003-SYN
- Date: 2026-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Walter Brandt-Ochoa, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review, seen the same day by hepatology. **S**

## History of present illness

Mr. Hemingway returns two weeks after intake and is seen by Dr. Solheim of hepatology on the same day. The HFE test drawn at intake shows that he is homozygous for C282Y. He has taken naltrexone 50 mg daily; he had mild nausea for three days, which passed. By his diary he has cut down from about ten drinks a day to five or six, with none before evening on most days. He has had no tremor, sweats or trouble sleeping beyond his usual. He has taken sertraline 50 mg daily with loose stools for a few days and no other side effects. His home blood pressure average is 146/90 on amlodipine 5 mg. His guns were taken to the locked storage at his shooting club the week after intake, and he keeps no ammunition at home. He has started weekly psychotherapy. His headaches are unchanged, two or three a week. **S**

| Element | Detail |
|---|---|
| HFE genotype | C282Y homozygous |
| Alcohol | Five or six drinks a day, down from about ten; none before evening |
| Naltrexone | 50 mg daily; nausea for three days, now gone |
| Sertraline | 50 mg daily for two weeks; loose stools for a few days |
| Home blood pressure | Average 146/90 |
| Firearms | Stored at his shooting club since last week; no ammunition at home |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; tiredness unchanged |
| Gastrointestinal | Positive | Nausea for three days on starting naltrexone, now gone; no abdominal pain or jaundice |
| Neurological | Positive | Headaches two or three times a week; no tremor |
| Psychiatric | Positive | Mood still low; no thoughts of suicide or wishes to be dead since the last visit |

4 systems reviewed. **S**

## Current medications

- Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinking **S**
- Thiamine 100 mg oral tablet, one tablet daily **S**
- Sertraline 50 mg oral tablet, one tablet daily **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 144/90 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 97.4 kg; BMI 29.1 kg/m². All vital signs are synthetic.

AST: 58 U/L (high); ALT: 66 U/L (high); GGT: 160 U/L (high); Ferritin: 1395 ng/mL (high); Liver stiffness (transient elastography): 9.4 kPa (high). All results are synthetic.

## Change since baseline

- AST: 70 U/L (high) at baseline, 58 U/L (high) at this visit **S**
- ALT: 78 U/L (high) at baseline, 66 U/L (high) at this visit **S**
- GGT: 196 U/L (high) at baseline, 160 U/L (high) at this visit **S**
- Ferritin: 1460 ng/mL (high) at baseline, 1395 ng/mL (high) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert; no smell of alcohol; blood pressure 144/90, pulse 84; weight 97.4 kg |
| Abdomen | Liver edge palpable 1 cm below the costal margin, smooth and non-tender; no spleen felt; no ascites |
| Skin | No jaundice, spider naevi or palmar erythema; no bronze pigmentation |
| Neurological | No tremor; gait steady |
| Psychiatric | Engaged and direct; mood low |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hereditary hemochromatosis, C282Y homozygous** (E83.110). C282Y homozygosity with a transferrin saturation of 76% and a ferritin over 1,000 ng/mL confirms hereditary hemochromatosis with iron overload. Because the ferritin is over 1,000 ng/mL and the ALT is raised, the liver must be staged. Dr. Solheim's elastography today is indeterminate at 9.4 kPa, which recent drinking may raise, so an MRI with liver iron quantification and elastography is planned instead of a biopsy. **S**
   - Weekly phlebotomy of 500 mL from next week, with a hemoglobin check before each session.
   - MRI of the liver with iron quantification and elastography.
   - No iron or vitamin C supplements; no raw shellfish.
   - A letter explaining HFE testing for first-degree relatives, which he may share as he chooses.
2. **Alcohol use disorder, severe, on naltrexone** (F10.20). Halved his drinking in two weeks on naltrexone, without withdrawal symptoms. Dr. Solheim advised that alcohol and iron overload together greatly raise the risk of cirrhosis, and that stopping would be best for his liver. He wants to keep cutting down first and decide about stopping when the MRI is back. Liver tests are falling. **S**
   - Continue naltrexone 50 mg daily and thiamine 100 mg daily.
   - Reduce by about one drink a day each week; call for tremor, sweating, racing heart or confusion.
3. **Depression** (F32.1). Two weeks on sertraline 50 mg with minor side effects. Safety reviewed: no thoughts of suicide or wishes to be dead since the last visit; firearms stored off-site; the 988 Suicide & Crisis Lifeline in his phone. **S**
   - Continue sertraline 50 mg daily.
   - Weekly psychotherapy.
4. **Hypertension** (I10). Home average 146/90 after two weeks on amlodipine 5 mg and less alcohol; too early to judge the full effect. **S**
   - Continue amlodipine 5 mg daily and home readings.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HFE genotyping | Once, when transferrin saturation is 45% or more with a raised ferritin | Completed today | C282Y homozygous (result of the intake sample, reported as narrative) |
| Laboratory | Serum ferritin during induction phlebotomy | At diagnosis, then about every 10 to 12 phlebotomies; target 50 to 100 ng/mL | Completed today | Ferritin 1,395 ng/mL before the first phlebotomy |
| Laboratory | Transferrin saturation | At diagnosis and as ferritin nears target | Up to date | 76% at intake |
| Imaging | Liver fibrosis staging (ferritin over 1,000 ng/mL and raised ALT) | Once at diagnosis: elastography, MRI or biopsy | Completed today | Transient elastography 9.4 kPa (indeterminate); controlled attenuation parameter 288 dB/m; MRI with iron quantification and elastography ordered instead of a biopsy |
| Medication safety | Weekly phlebotomy of 500 mL | Weekly during induction | Ordered | First session next week |
| Self-management | Diet: no iron or vitamin C supplements, no raw shellfish | Every visit | Completed today | Explained with a written sheet; he takes no supplements |
| Referral | Testing offered to first-degree relatives | At diagnosis | Completed today | Letter for first-degree relatives given to him; whether to share it is his choice; no relative's result is recorded |
| Laboratory | Liver tests on naltrexone | Baseline, about one month, then every three to six months | Completed today | AST 58, ALT 66 and GGT 160 U/L, falling from 70, 78 and 196 |
| Survey | Drinking quantity and goal (AUDIT-C, drinking diary) | Every visit | Completed today | Diary: five or six drinks a day; AUDIT-C next at the six-week visit |
| Medication safety | Opioid use and pain plan on naltrexone | Every visit | Completed today | No opioids; wallet card explaining naltrexone |
| Examination | Alcohol withdrawal risk and symptoms when cutting down or stopping | Each visit while cutting down | Completed today | No tremor, sweating or tachycardia; reducing gradually |
| Medication safety | Thiamine | Daily while drinking heavily | Completed today | Taking thiamine 100 mg daily |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Up to date | PHQ-9 16 two weeks ago; next at the six-week visit |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | Two-week review: loose stools for a few days; continue 50 mg |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; firearms stored off-site; safety plan reviewed |
| Self-management | Psychotherapy (CBT) | Weekly | Completed today | First session last week |
| Examination | Blood pressure, home readings, weight and cardiac auscultation | Every visit | Completed today | 144/90 in clinic; home average 146/90; weight 97.4 kg; no murmur |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension | Ordered | Ordered at intake; not yet scheduled |
| Examination | Post-concussion symptoms (headache frequency, sleep, concentration) | Every visit | Completed today | Headaches two or three times a week; sleeping six hours |
| Referral | Hepatology consultation | At diagnosis of iron overload with raised liver tests | Completed today | Seen by Dr. Solheim today |

## Goal progress

- Drinking goal chosen by him: no more than two drinks a day and none before evening, then reconsidered once the liver results are known. In progress; target 2026-06-08. **S**
- Ferritin 50 to 100 ng/mL with weekly phlebotomy, then maintenance. In progress; target 2026-08-31. **S**
- PHQ-9 below 5. In progress; target 2026-08-31. **S**
- Blood pressure below 130/80 mmHg. In progress; target 2026-08-31. **S**
- Fewer headaches and clearer thinking, so that he can write. In progress; target 2026-08-31. **S**

## Guideline basis

- Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011), American Association for the Study of Liver Diseases (Hepatology 2011;54(1):328-343)
- ACG Clinical Guideline: Hereditary Hemochromatosis (2019), American College of Gastroenterology (Am J Gastroenterol 2019;114(8):1202-1218)
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026), Aether Forge

## Follow-up

- Weekly phlebotomy from next week. MRI of the liver within four weeks. Six-week review in four weeks with blood count, ferritin, liver tests, PHQ-9 and AUDIT-C. Weekly psychotherapy. **S**
- Next scheduled visit 2026-04-13: six-week review: phlebotomy, drinking, mood, blood pressure and liver imaging. **S**
